

DETAILED ACTION

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ginger Dreger on September 25, 2003.

The application has been amended as follows:

10 IN THE CLAIMS:

Cancel claim 27.

Replace claim 28 with the following claim:

28. A constrained helical peptide comprising a sequence of nine amino acid residues having a first terminal residue and a second terminal residue, wherein said [15] residues flank an internal sequence of seven amino acids and have side-chains covalently bonded to each other to form a locking moiety and thereby constrain the peptide, wherein F¹ said peptide inhibits the binding of IGF-I to IGFBP-1, and wherein the internal sequence is Xaa(7)LeuAlaXaa(10) Xaa(11)Xaa(12)Xaa(13) (SEQ ID NO:31), wherein Xaa(7), Xaa(11), Xaa(12), and Xaa(13) are independently Nal(1), Lys, His, Phe, Trp, Tyr, Pro, [20] Gln, or Met, and Xaa(10) is any amino acid.
